247 related articles for article (PubMed ID: 18594845)
1. Predictive and prognostic value of microsatellite instability in patients with advanced colorectal cancer treated with a fluoropyrimidine and oxaliplatin containing first-line chemotherapy. A report of the AIO Colorectal Study Group.
Müller CI; Schulmann K; Reinacher-Schick A; Andre N; Arnold D; Tannapfel A; Arkenau H; Hahn SA; Schmoll SH; Porschen R; Schmiegel W; Graeven U;
Int J Colorectal Dis; 2008 Nov; 23(11):1033-9. PubMed ID: 18594845
[TBL] [Abstract][Full Text] [Related]
2. The effect of DNA mismatch repair (MMR) status on oxaliplatin-based first-line chemotherapy as in recurrent or metastatic colon cancer.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Chun HK; Lee WY; Park YS
Med Oncol; 2010 Dec; 27(4):1277-85. PubMed ID: 19949897
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of microsatellite instability and p53 expression in metastatic colorectal cancer treated with oxaliplatin and fluoropyrimidine-based chemotherapy.
Nöpel-Dünnebacke S; Schulmann K; Reinacher-Schick A; Porschen R; Schmiegel W; Tannapfel A; Graeven U
Z Gastroenterol; 2014 Dec; 52(12):1394-401. PubMed ID: 25474278
[TBL] [Abstract][Full Text] [Related]
4. Microsatellite instability and sensitivity to fluoropyrimidine and oxaliplatin containing first-line chemotherapy in metastatic colorectal cancer.
Liu J; Wang B; Fang W
Eur J Hosp Pharm; 2020 Sep; 27(5):267-270. PubMed ID: 32839257
[TBL] [Abstract][Full Text] [Related]
5. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
[TBL] [Abstract][Full Text] [Related]
6. Correlations between microsatellite instability, ERCC1/XRCC1 polymorphism and clinical characteristics, and FOLFOX adjuvant chemotherapy effect of colorectal cancer patients.
Zhang L; Zhao J; Yu B; Song X; Sun G; Han L; Wang L; Dong S
Cancer Genet; 2017 Dec; 218-219():51-57. PubMed ID: 29153096
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability: a predictive marker in metastatic colorectal cancer?
Des Guetz G; Uzzan B; Nicolas P; Schischmanoff O; Morere JF
Target Oncol; 2009 Jan; 4(1):57-62. PubMed ID: 19343302
[TBL] [Abstract][Full Text] [Related]
8. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and predictive relevance of microsatellite instability in colorectal cancer.
Storojeva I; Boulay JL; Heinimann K; Ballabeni P; Terracciano L; Laffer U; Mild G; Herrmann R; Rochlitz C
Oncol Rep; 2005 Jul; 14(1):241-9. PubMed ID: 15944796
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite instability (MSI-H) is associated with a high immunoscore but not with PD-L1 expression or increased survival in patients (pts.) with metastatic colorectal cancer (mCRC) treated with oxaliplatin (ox) and fluoropyrimidine (FP) with and without bevacizumab (bev): a pooled analysis of the AIO KRK 0207 and RO91 trials.
Noepel-Duennebacke S; Juette H; Schulmann K; Graeven U; Porschen R; Stoehlmacher J; Hegewisch-Becker S; Raulf A; Arnold D; Reinacher-Schick A; Tannapfel A
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3063-3072. PubMed ID: 33675399
[TBL] [Abstract][Full Text] [Related]
11. Is There a Role for Programmed Death Ligand-1 Testing and Immunotherapy in Colorectal Cancer With Microsatellite Instability? Part I-Colorectal Cancer: Microsatellite Instability, Testing, and Clinical Implications.
Marginean EC; Melosky B
Arch Pathol Lab Med; 2018 Jan; 142(1):17-25. PubMed ID: 29144791
[TBL] [Abstract][Full Text] [Related]
12. Microsatellite instability & survival in patients with stage II/III colorectal carcinoma.
Srdjan M; Jadranka A; Ivan D; Branimir Z; Daniela B; Petar S; Velimir M; Zoran K
Indian J Med Res; 2016 May; 143(Supplement):S104-S111. PubMed ID: 27748284
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of reduced SMAD4 expression in patients with metastatic colorectal cancer under oxaliplatin-containing chemotherapy: a translational study of the AIO colorectal study group.
Baraniskin A; Munding J; Schulmann K; Meier D; Porschen R; Arkenau HT; Graeven U; Schmiegel W; Tannapfel A; Reinacher-Schick A
Clin Colorectal Cancer; 2011 Mar; 10(1):24-9. PubMed ID: 21609932
[TBL] [Abstract][Full Text] [Related]
14. Microsatellite instability did not predict individual survival of unselected patients with colorectal cancer.
Lamberti C; Lundin S; Bogdanow M; Pagenstecher C; Friedrichs N; Büttner R; Sauerbruch T
Int J Colorectal Dis; 2007 Feb; 22(2):145-52. PubMed ID: 16724208
[TBL] [Abstract][Full Text] [Related]
15. Microsatellite instability and sensitivitiy to FOLFOX treatment in metastatic colorectal cancer.
des Guetz G; Mariani P; Cucherousset J; Benamoun M; Lagorce C; Sastre X; Le Toumelin P; Uzzan B; Perret GY; Morere JF; Breau JL; Fagard R; Schischmanoff PO
Anticancer Res; 2007; 27(4C):2715-9. PubMed ID: 17695437
[TBL] [Abstract][Full Text] [Related]
16. Randomized phase III clinical trial comparing the combination of capecitabine and oxaliplatin (CAPOX) with the combination of 5-fluorouracil, leucovorin and oxaliplatin (modified FOLFOX6) as adjuvant therapy in patients with operated high-risk stage II or stage III colorectal cancer.
Pectasides D; Karavasilis V; Papaxoinis G; Gourgioti G; Makatsoris T; Raptou G; Vrettou E; Sgouros J; Samantas E; Basdanis G; Papakostas P; Bafaloukos D; Kotoula V; Kalofonos HP; Scopa CD; Pentheroudakis G; Fountzilas G
BMC Cancer; 2015 May; 15():384. PubMed ID: 25956750
[TBL] [Abstract][Full Text] [Related]
17. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy.
Hemminki A; Mecklin JP; Järvinen H; Aaltonen LA; Joensuu H
Gastroenterology; 2000 Oct; 119(4):921-8. PubMed ID: 11040179
[TBL] [Abstract][Full Text] [Related]
18. Prognosis and chemosensitivity of deficient MMR phenotype in patients with metastatic colorectal cancer: An AGEO retrospective multicenter study.
Tougeron D; Sueur B; Zaanan A; de la Fouchardiére C; Sefrioui D; Lecomte T; Aparicio T; Des Guetz G; Artru P; Hautefeuille V; Coriat R; Moulin V; Locher C; Touchefeu Y; Lecaille C; Goujon G; Ferru A; Evrard C; Chautard R; Gentilhomme L; Vernerey D; Taieb J; André T; Henriques J; Cohen R;
Int J Cancer; 2020 Jul; 147(1):285-296. PubMed ID: 31970760
[TBL] [Abstract][Full Text] [Related]
19. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial.
Hegewisch-Becker S; Graeven U; Lerchenmüller CA; Killing B; Depenbusch R; Steffens CC; Al-Batran SE; Lange T; Dietrich G; Stoehlmacher J; Tannapfel A; Reinacher-Schick A; Quidde J; Trarbach T; Hinke A; Schmoll HJ; Arnold D
Lancet Oncol; 2015 Oct; 16(13):1355-69. PubMed ID: 26361971
[TBL] [Abstract][Full Text] [Related]
20. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
Sastre J; Orden V; Martínez A; Bando I; Balbín M; Bellosillo B; Palanca S; Peligros Gomez MI; Mediero B; Llovet P; Moral VM; Viéitez JM; García-Alfonso P; Calle SG; Ortiz-Morales MJ; Salud A; Quintero G; Lopez C; Díaz-Rubio E; Aranda E;
Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]